Skip to search formSkip to main contentSkip to account menu

Anti-ErbB3 Monoclonal Antibody KTN3379

Known as: KTN3379 
A monoclonal antibody directed against the human epidermal growth factor receptor ErbB3 (Her3) with potential antineoplastic activity. Anti-ErbB3… 
National Institutes of Health

Related topics

Related topics

1 relation
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Safety, pharmacokinetics (PK), pharmacodynamics (Pd), and antitumor activity in a phase 1b study evaluating anti-ErbB3 antibody KTN3379 in adults with advanced tumors alone and with targeted…
2501Background: KTN3379 is a fully human anti-ErbB3 antibody with YTE half-life extension engineering that uniquely binds domain… 
2016
2016
Abstract 1196: Combination of neuregulin with EGFR activation signatures predict activity of the anti-ErbB3 antibody KTN3379 in SCCHN
ErbB3, the kinase-dead member of the EGFR/ErbB family, has been implicated as an oncogenic driver in a number of solid tumor… 
2016
2016
Abstract 1205: HER3 is a functional molecular target in HPV-associated head and neck cancer
Background: Head and neck squamous cell carcinoma (HNSCC) is an aggressive cancer with a rising incidence of more than 600,000… 
2016
2016
Abstract 3053: Inhibition of heregulin-mediated ErbB3 signaling as a radiosensitization therapy for head and neck cancers
PURPOSE: EGFR signaling confers resistance to radiation therapy (RT) and is a validated target in head and neck squamous cell… 
2016
2016
Abstract 2979: Dual targeting of HER3 and PIK3CA has potent anti-tumor effects in pre-clinical models of HNSCC
Background: The phosphoinositide 3-kinase (PI3K) pathway is a frequently mutated oncogenic pathway in head and neck squamous cell… 
2015
2015
A phase 1, open-label study to evaluate the safety and pharmacokinetics of the anti ErbB3 antibody, KTN3379, alone or in combination with targeted therapies in patients with advanced tumors.
2598 Background: KTN3379 is a human monoclonal antibody against a unique epitope of human epidermal growth factor receptor-3… 
2015
2015
Abstract 2615: Dual ErbB blockade with KTN3379 and cetuximab yields enhanced antitumor activity by inhibiting parallel signaling pathways in SCCHN
2015
2015
Abstract 1672: Structural basis for inhibition of ligand-dependent and -independent ErbB3 activation by KTN3379
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA ErbB3 signaling plays an important role in the… 
2014
2014
407 Structural basis for inhibition of ligand-dependent and -independent ErbB3 activation by KTN3379
2014
2014
210 A phase 1 study of KTN3379, a human anti-ErbB3 monoclonal antibody in patients with advanced cancers
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)